West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway

West Pharmaceutical Services, Inc. (NYSE:WST) is included among the Dividend Kings and Aristocrats List: 32 Biggest Stocks.

West Pharmaceutical CEO Plans Exit after 11 Years, Succession Process Underway

On March 9, Reuters reported that West Pharmaceutical Services, Inc. (NYSE:WST)’s chief executive, Eric Green, plans to retire once the company names his successor, ending an 11-year tenure in the role. The Pennsylvania-based company expects the transition to take place in the second half of 2026. It has brought in an executive search firm to manage the process.

“After serving 11 years as the Company’s 6th CEO over the past century, it is time for someone else to take over the leadership of West,” Green said in a statement. Green stepped into the CEO role in 2015 and became board chair in 2022. He said the move will give him time to pursue board and advisory positions going forward. During his time leading the company, West more than doubled its sales and delivered a total shareholder return of roughly 350%, according to lead independent director Robert Friel.

The company manufactures components and devices used to deliver injectable drugs, including treatments for diabetes and obesity. Last month, West said demand for GLP-1 therapies is expected to keep growing in 2026, though not at the same pace seen in 2025.

West Pharmaceutical Services, Inc. (NYSE:WST) operates as a global manufacturer focused on designing and producing integrated containment and delivery systems for injectable drugs and healthcare products.

While we acknowledge the risk and potential of WST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than WST and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Dividend Stocks to Buy for Steady Income and 14 Under-the-Radar High Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.